Thursday, October 29, 2020
Voluntis, a leader in digital therapeutics, announced today its strategic partnership with Redox, the leading interoperability platform for healthcare data exchange. The partnership will allow providers to automate and adapt insights on their patients’ treatment journey within their Electronic Health Records (EHR) to enhance care and collaboration. Redox and Voluntis will work together in an effort to improve the integration of digital therapeutics as part of routine clinical practice and enrich EHR data with actionable insights on how patients experience their treatment at home. Clinical staff will be better equipped to anticipate and implement responsive care strategies that work to serve each patient’s individual needs when they need it most.
“Digital therapeutics are the next disruptive force in the healthcare industry. They offer personalized therapeutic interventions for patients that are configured by their care team and backed by clinical evidence,” said Voluntis CEO Pierre Leurent. “With the collaboration of Redox, we intend to strengthen the ability of our Theraxium platform, and the digital therapeutics it supports, to work seamlessly with EHRs and be a fully integrated component of routine care.”
As part of the collaboration, the two companies will integrate Voluntis’ digital therapeutics platform, Theraxium, with Redox’ interoperability platform. The new capabilities will benefit all the solutions developed by Voluntis together with or on behalf of its life sciences partners.
Today, more than 900 healthcare organizations using 55 EHR vendors trust Redox to strategically integrate digital health solutions into their day-to-day operations. Through this partnership, the Voluntis portfolio of products are immediately interoperable with any organization using Redox for healthcare data exchange to optimize the provider and patient experience.
“As we navigate a challenging time in healthcare, it’s exciting to see companies like Voluntis paving the way for the future of how digital health solutions are brought to market and the extensive value they deliver,” said Niko Skievaski, co-founder and president at Redox. “Putting the power of information directly into the hands of providers and patients will help ensure actionable insights for these individuals living with chronic and rare diseases and will change the trajectory of coordinated care. We’re proud of our work with Voluntis to find more advanced ways to create a frictionless information workflow to improve care and outcomes.”
About Voluntis
Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit www.voluntis.com, or follow us on Linkedin and Twitter.
Mnemo : VTX - ISIN : FR0004183960
About Redox
Redox accelerates the development and distribution of healthcare software solutions with a full-service integration platform to securely and efficiently exchange healthcare data. With just one connection, data can be transmitted across a growing network of 1,000 live connections in more than 900 healthcare delivery organizations and 250 independent software vendors in every state across the country. Redox regularly exchanges more than 11 million patient records per day, leveraging a single data standard compatible with more than 55 electronic health record systems. Learn how you can leverage the Redox platform at www.redoxengine.com. Please follow us on Twitter and LinkedIn.
Disclaimer
This press release contains certain forward-looking statements concerning Voluntis group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Voluntis considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2019 annual financial report and the 2020 half-year financial report published by Voluntis respectively on April 30, 2020 and September 29, 2020 (a copy of which is available on www.voluntis.com) and to the development of economic conditions, financial markets and the markets in which Voluntis operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Voluntis or not currently considered material by Voluntis. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Voluntis to be materially different from such forward-looking statements. Voluntis expressly declines any obligation to update such forward-looking statements.
Contacts
For Voluntis
ACTUS
Media Relations
Vivien Ferran
vferran@actus.fr
+33 (0)1 53 67 36 34
ACTUS
Investor Relations
Jérôme Fabreguettes-Leib
voluntis@actus.fr
+33 (0)1 53 67 36 78
Voluntis
Chief Financial Officer
Guillaume Floch
investisseurs@voluntis.com
+33 (0)1 41 38 39 20
For Redox
Look Left Marketing
Davida Dinerman
press@redoxengine.com
+1 508 561 4263
